Loading...

FITC anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1.5_FITC_102110
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
  • GK1.5_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100405 50 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100406 500 µg 80€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  2. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  3. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  4. Liu J, et al. 2021. Front Immunol. 12:747730. PubMed
  5. Su Y, et al. 2022. J Hematol Oncol. 15:99. PubMed
  6. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  7. Mills EL, et al. 2022. Cell Metab. 34:140. PubMed
  8. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  9. Wu R, et al. 2022. J Dermatol. 49:432. PubMed
  10. Mi Z, et al. 2021. Vaccines (Basel). 10: . PubMed
  11. Corral D, et al. 2022. Cell Rep. 39:110715. PubMed
  12. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  13. Shen Z, et al. 2022. EBioMedicine. 85:104285. PubMed
  14. Balood M, et al. 2022. Nature. 611:405. PubMed
  15. Zhu M, et al. 2022. Front Immunol. 13:1019248. PubMed
  16. Zhang Z, et al. 2022. Integr Cancer Ther. 21:15347354221138534. PubMed
  17. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  18. Wang H, et al. 2022. J Nanobiotechnology. 20:513. PubMed
  19. Chen C, et al. 2022. J Neuroinflammation. 19:315. PubMed
  20. Qin S, et al. 2023. Acta Pharm Sin B. :. PubMed
  21. Merk VM, et al. 2023. Genes Immun. 24:52. PubMed
  22. Meng S, et al. 2023. Stem Cell Investig. 10:2. PubMed
  23. Sun Y, et al. 2023. Cell Mol Life Sci. 80:63. PubMed
  24. Hajjar S, et al. 2022. Cell Death Differ. 29:585. PubMed
  25. Sylvester MA, et al. 2022. Am J Physiol Renal Physiol. 322:F245. PubMed
  26. Zander R, et al. 2022. Immunity. 55:475. PubMed
  27. Li Z, et al. 2022. Nat Commun. 13:1845. PubMed
  28. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  29. Qiu Z, et al. 2022. J Exp Med. 219:. PubMed
  30. Lin J, et al. 2022. Adv Sci (Weinh). 9:e2202633. PubMed
  31. Hamdi L, et al. 2022. Ann Clin Transl Neurol. 9:1792. PubMed
  32. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  33. Zhu C, et al. 2022. Chemotherapy. 67:211. PubMed
  34. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  35. Wilson NG, et al. 2023. iScience. 26:105991. PubMed
  36. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  37. Mackin S, et al. 2023. Nat Microbiol. 8:569. PubMed
  38. Shi Y, et al. 2023. Nat Commun. 14:1884. PubMed
  39. Liu H, et al. 2023. Breast Cancer Res. 25:43. PubMed
  40. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  41. Fiedler T, et al. 2023. J Neuroinflammation. 20:100. PubMed
  42. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  43. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  44. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
  45. Peymanfar Y, et al. 2023. Int J Mol Sci. 24:. PubMed
  46. Wang X, et al. 2023. Nat Commun. 14:3440. PubMed
  47. Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed
  48. Iwanami N, et al. 2023. Nat Commun. 14:3645. PubMed
  49. Solvay M, et al. 2023. J Immunother Cancer. 11:. PubMed
  50. Wang Z, et al. 2023. Sci Adv. 9:eabo4100. PubMed
  51. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
  52. Katsumura KR, et al. 2018. Proc Natl Acad Sci U S A. 115:E10109. PubMed
  53. Valanparambil RM, et al. 2017. PLoS Pathog. 13:e1006647. PubMed
  54. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  55. Rosenkranz SC, et al. 2021. eLife. 10:00. PubMed
  56. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  57. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  58. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  59. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  60. He R, et al. 2021. J Immunol. 206:2353. PubMed
  61. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  62. Fan L, et al. 2021. Cancers (Basel). 13:. PubMed
  63. Wu N, et al. 2020. Cell Rep. 30:1129. PubMed
  64. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  65. Sega E, et al. 2008. Int J Radiat Oncol Biol Phys. 71:559. PubMed
  66. Lua Y, et al. 2012. Mol Immunol. 52:229. PubMed
  67. Zasłona Z, et al. 2014. J Immunol. 193:4245. PubMed
  68. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  69. Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed
  70. Luo R, et al. 2021. Theranostics. 11:117. PubMed
  71. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  72. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  73. Jiang W, et al. 2022. Front Immunol. 13:878832. PubMed
  74. Toomer G, et al. 2022. Viruses. 14:. PubMed
  75. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  76. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  77. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  78. Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed
  79. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  80. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  81. Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed
  82. Jazowiecka-Rakus J, et al. 2021. Cancers (Basel). 13:. PubMed
  83. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  84. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  85. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  86. Pobezinskaya EL et al. 2019. Front Immunol. 1.079861111 . PubMed
  87. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  88. Guan H, et al. 2012. PLoS One. 7:e35650. PubMed
  89. D Kim, S Lee, H Jun 2016. Immunol Cell Biol. 10.1038/icb.2016.98. PubMed
  90. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  91. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
  92. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  93. Aqel SI, et al. 2021. JCI Insight. 6:e142376. PubMed
  94. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  95. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  96. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  97. Zhou HF, et al. 2022. Front Pharmacol. 13:778755. PubMed
  98. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  99. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  100. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  101. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  102. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  103. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  104. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  105. White C, et al. 2014. J Immunol. 193:5933. PubMed
  106. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  107. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  108. Anastasiou M, et al. 2021. JCI Insight. 6:. PubMed
  109. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  110. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  111. Thomas S, et al. 2019. J Immunother Cancer. 7:214. PubMed
  112. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
  113. Ma X, et al. 2021. Cell Metabolism. 33(5):1001-1012.e5. PubMed
  114. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  115. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  116. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  117. Feng H, et al. 2020. J Dermatol. 47:147. PubMed
  118. Ren HZ, et al. 2022. J Clin Transl Hepatol. 10:1138. PubMed
  119. Zongyi Y, et al. 2017. PLoS One. 10.1371/journal.pone.0189617. PubMed
  120. Wang Z, et al. 2020. J Clin Invest. 130:3717. PubMed
  121. Raineri D, et al. 2021. Biomedicines. 10:. PubMed
  122. He X, et al. 2021. Small. 17:e2007165. PubMed
  123. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  124. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  125. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  126. Pedraza–Zamora CP, et al. 2017. Parasite Immunol. 39:4. PubMed
  127. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  128. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  129. Deng Z, et al. 2020. World J Gastrointest Oncol. 1091:12. PubMed
  130. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  131. Wang Z, et al. 2022. Nat Biomed Eng. 6:791. PubMed
  132. Guo P, et al. 2021. J Immunol. 207:408. PubMed
  133. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  134. Cervera–Carrascon V, et al. 2020. Oncoimmunology. 9:1761229. PubMed
  135. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  136. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  137. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  138. Ahmari N, et al. 2016. Physiol Genomics. 48: 526 - 536. PubMed
  139. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  140. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  141. Zhou H, et al. 2022. Oncoimmunology. 11:2057892. PubMed
  142. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  143. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  144. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  145. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  146. Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed
  147. Dmitrieva‐Posocco O et al. 2019. Immunity. 50(1):166-180 . PubMed
  148. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  149. Niknam S, et al. 2018. Clin Cancer Res. 24:5735. PubMed
  150. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  151. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  152. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  153. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  154. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  155. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  156. Zhu Y, et al. 2021. EMBO J. 40:e105320. PubMed
  157. Wang Y, et al. 2021. Front Microbiol. 12:701566. PubMed
  158. Gebre MS, et al. 2022. NPJ Vaccines. 7:88. PubMed
  159. Yang B, et al. 2022. Bioengineered. 13:2685. PubMed
  160. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  161. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  162. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  163. Mencl S, et al. 2014. J Neuroimmunol. 274:125. PubMed
  164. Sun H, et al. 2022. Front Immunol. 13:818017. PubMed
  165. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  166. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  167. Lang V, et al. 2021. Elife. 10:. PubMed
  168. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed
  169. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  170. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  171. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  172. Zhou J, et al. 2019. Nat Commun. 10:2427. PubMed
  173. Kmieciak M, et al. 2011. J Vis Exp. 47: 2381. PubMed
  174. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  175. Timilshina M, et al. 2017. PLoS One. 10.1371/journal.pone.0168942. PubMed
  176. Wang X, et al. 2020. Nat Commun. 4.505555556. PubMed
  177. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  178. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  179. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  180. Ma K, et al. 2022. iScience. 25:104347. PubMed
  181. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  182. Gao X, et al. 2022. Front Immunol. 13:799331. PubMed
  183. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  184. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  185. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  186. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  187. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  188. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  189. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  190. Zan H, et al. 2017. Nat Commun. 8:14244. PubMed
  191. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  192. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  193. Takaku S, et al. 2022. Evid Based Complement Alternat Med. 2022:6122955. PubMed
  194. Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed
  195. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  196. Li J, et al. 2020. Development. :. PubMed
  197. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  198. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  199. Kamata T, et al. 2020. Cell Reports. 31(12):107802. PubMed
  200. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  201. Reynolds CJ, et al. 2018. Sci Rep. 8:672. PubMed
  202. Ligon MM, et al. 2020. Mucosal Immunol. 1.172222222. PubMed
  203. Da Mesquita S, et al. 2021. Science Advances. 7(21):. PubMed
  204. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  205. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  206. Jazowiecka-Rakus J, et al. 2020. Mol Ther Oncolytics. 18:335. PubMed
  207. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  208. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  209. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  210. Nechama M, et al. 2018. Nat Commun. 9:1603. PubMed
  211. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  212. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  213. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  214. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  215. Pan L, et al. 2022. Front Immunol. 13:837497. PubMed
  216. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  217. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  218. Zhou H, et al. 2021. Cell Death Discov. 7:332. PubMed
  219. Liu Y, et al. 2020. Cell Death Dis. 11:1062. PubMed
  220. Khosravi N, et al. 2018. Cancer Immunol Res. 0.797222222. PubMed
  221. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  222. Ji L et al. 2019. Immunity. 51(2):272-284 . PubMed
  223. Habtetsion T et al. 2018. Cell metabolism. 28(2):228-242 . PubMed
  224. Coley WD et al. 2018. F1000Research. 2018 Mar 14 [revised 2018 Jan 1] 0.5125. PubMed
  225. Bryan Hart, Sunhee Lee 2016. PLoS Negl Trop Dis. 10:e0005229. PubMed
  226. Blaszczak AM, et al. 2020. Immunometabolism. 2:00. PubMed
  227. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  228. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  229. Zhong C, et al. 2021. J Virol. 95:e0092521. PubMed
  230. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  231. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  232. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  233. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  234. Sears SM, et al. 2022. Kidney360. 3:818. PubMed
  235. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  236. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  237. Zhao Y, et al. 2020. Front Immunol. 2.572222222. PubMed
  238. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  239. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  240. Hart B, et al. 2015. PLoS Negl Trop Dis. 9: 0004046. PubMed
  241. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
  242. Wang Y, et al. 2022. Nat Commun. 13:1454. PubMed
  243. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  244. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  245. Li Z, et al. 2022. Evid Based Complement Alternat Med. 2022:7421265. PubMed
  246. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  247. Ramanan D, et al. 2020. Cell. 181(6):1276-1290. PubMed
  248. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  249. Blaszczak AM, et al. 2019. J Immunol. 202:2451. PubMed
  250. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  251. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  252. Gardenier J, et al. 2017. Nat Commun. 8:14345. PubMed
  253. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  254. Zeng A, et al. 2020. Oncol Rep. . PubMed
  255. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  256. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  257. Chen Y, et al. 2021. Braz J Med Biol Res. 54:e9570. PubMed
  258. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  259. Kathania M, et al. 2022. Cell Rep. 40:111345. PubMed
  260. Gawish R, et al. 2022. Elife. 11:. PubMed
  261. Li J, et al. 2022. Nat Commun. 13:1481. PubMed
  262. Bartley A, et al. 2018. Front Physiol. 9:1593. PubMed
  263. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  264. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  265. Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed
  266. Cortez MA, et al. 2020. Nat Commun. 3.819444444. PubMed
  267. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  268. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  269. Lestari SR, et al. 2020. J Ayurveda Integr Med. 11:414. PubMed
  270. Jiang W, et al. 2021. Cell Rep. 37:110112. PubMed
  271. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  272. Ding X, et al. 2021. Front Immunol. 12:667136. PubMed
  273. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
RRID
AB_312690 (BioLegend Cat. No. 100405)
AB_312690 (BioLegend Cat. No. 100406)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD4
Specificity Alt (DOES NOT SHOW ON TDS):
CD4
App Abbreviation (DOES NOT SHOW ON TDS):
FC,IHC-F,ICC
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Spark PLUS UV395™ anti-mouse CD4 GK1.5 FC
Spark Red™ 718 anti-mouse CD4 (Flexi-Fluor™) GK1.5 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account